For further details see:
Idera says AbbVie has discontinued enrollment in its study for tilsotolimod comboFor further details see:
Idera says AbbVie has discontinued enrollment in its study for tilsotolimod comboMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
AbbVie to Host Second-Quarter 2024 Earnings Conference Call PR Newswire NORTH CHICAGO, Ill. , July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024 , before the market opens. AbbVie wi...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer PR Newswire As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A. Michael Joins AbbVie Board of Directors NORTH CHICAGO, Ill....